NEU
Neuren Pharmaceuticals Ltd
$19.64
▼ -2.82%
Market cap
$2.49B
Turnover
$6,089,863
Last price
$19.64
Day change
-2.82%
Announcements
10
Range, past year
Open 20.47 · Low 10.91 · Now 19.64 · High 23.76
Open NEU in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
NEU momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
34/100
Wyckoff phase
Accumulation15d
Trend stage
Distribution
1 Day
-2.8%
1 Week
-2.8%
1 Month
-5.0%
1 Year
-4.2%
RSI
39
Avg daily range
3.6%
Neuren Pharmaceuticals Ltd scores 34 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Distribution.
On the Wyckoff cycle it sits in Accumulation, where it has been for 15 trading days. The weekly timeframe reads Uptrend, which does not yet agree with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads low.
Points to watch
- Risk rating: High
- Composite downside risk elevated
NEU announcements
Recent price-sensitive releases.
- 2026-09-29 Trofinetide US patent protections extended to March 2041 Progress Report
- 2026-09-29 Pause in Trading Notice Pending
- 2026-08-26 Growing royalty anchors Neuren first ever dividend program Dividend Reinvestment Plan | Half Yearly Report | Dividend Record Date | Dividend Pay Date | Dividend Rate
- 2026-08-26 Half Yearly Report and Accounts Half Yearly Report | Half Year Audit Review | Half Year Directors' Statement | Half Year Accounts | Half Year Directors' Report | Dividend Record Date | Dividend Pay Date | Dividend Rate
- 2026-08-25 European Commission grants marketing authorisation for DAYBU Progress Report
- 2026-08-05 Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded Progress Report
- 2026-06-29 DAYBU recommended for approval in the European Union
More Health Care stocks
Most traded in the same sector.